ClinicalTrials.gg
RecruitingNCT05948891TriNEXTUpdated Mar 13, 2024

Impact of Fixed TRIple Therapy With Beclometasone/Formoterol/Glycopyrronium DPI (Trimbow® in NEXThaler Device) in Chronic Obstructive PulmoNary Disease in rEal-world Settings: Health-related Quality of Life Patient' eXpectations and characterisTics: the TriNEXT Study

An observational study in COPD, sponsored by Chiesi SAS. Recruiting at 1 site in France. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2024-03-13.

Sponsored by Chiesi SAS (part of Chiesi Farmaceutici S.p.A.) · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
500
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A. — 5 open to participants now, 5 under way, none of them phase 3. Pulmonary Disease, Chronic Obstructive · Chiesi Farmaceutici S.p.A..

Started
2023
with 2 others
Observational
9 of 68
5 open now
Registered
62nd of 68
by date

Among the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., this one is one of 3 that started in 2023, is one of 9 observational ones, and was the 62nd registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

5 of the 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A. are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 68 studies in Pulmonary Disease, Chronic Obstructive by Chiesi Farmaceutici S.p.A., or all of them as a file.
02

Study summary

This is an observational, prospective, multicentric, cohort study conducted in France to evaluate the QoL in COPD patients treated with TRIMBOW NEXThaler 88/5/9 in a routine clinical practice setting. Patients enrolled in this study will be patients diagnosed with a COPD with a ratio of post-bronchodilator (salbutamol 400 μg) forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) of less than 0.7 to whom TRIMBOW NEXThaler 88/5/9 has been initiated by an hospital or local pulmonologists in accordance with clinical practice and marketing authorization.

Read the detailed description

The decision of patients to participate in this study must not, in any way, impact upon the standard of care that they are receiving or any benefits to which they are otherwise entitled. The treatment decision must have been taken prior to and independently of the patient's inclusion in the study. All aspects of treatment and clinical management of patients will be at the discretion of the participating pulmonologist (or treating pulmonologist where different) according to local clinical practice and applicable local regulations.

In addition to the data available per clinical practice, the participating pulmonologists will be asked to obtain patient-reported outcome measures (PROMs) data from patients within this study and to invite patients to wear a connected watch to record physical activity and sleep quality (50% of patients (about 250 patients) who first accept to wear the watch will be equipped).

The duration of a patient's participation in this study will be 6 months made of three visits (M0, M3, M6) according to routine clinical practice.

  • Visit 1 (M0); inclusion of patient when BDP/FF/GB NEXThaler® 88/5/9 is initiated;
  • Visit 2 (M3); 3 months (+/- 30 days) post BDP/FF/GB NEXThaler® 88/5/9 initiation;
  • Visit 3 (M6, last visit): 6 months (+/- 30 days) post BDP/FF/GB NEXThaler® 88/5/9 initiation;

The inclusion duration will be 12 to 15 months. The overall duration of the study, including recruitment and follow-up, is expected to be 21 months.

Data collection will be considered complete for a participating patient if data available at 6 have been recorded in the CRF and associated PROs completed. Patients will be followed until the end of the study period (M6) even if TRIMBOW NEXThaler 88/5/9 is discontinued.

03

Conditions studied

  • COPD

Keywords

  • Digital
  • QOL
  • PROMS
  • PRO
  • respiratory diseases
  • Chronic obstructive pulmonary disease (COPD)
  • Adult
  • observational
  • connected device
  • quality of life
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients participating in this non-interventional real-world evidence study will be COPD patients for whom it has been decided to initiate BDP/FF/G (88/5/9) in NEXThaler® device by a physician in accordance with clinical practice

All eligible patients should be offered enrolment for data collection within the study. Participating sites will be encouraged to propose the study to all patients satisfying eligibility criteria, in a consecutive manner, when patients come for their regular consultation, in order to minimize bias in patient selection. In any case, the treatment decision must have been taken by the investigator prior to, and independently of the patient's inclusion into the study, following standard clinical practice and regulations.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients aged ≥40 years
  • Diagnosis of with a ratio of post-bronchodilator (salbutamol 400 μg) in 1 s (FEV1) to forced vital capacity (FVC) of less than 0.7
  • Physicians' decision to start a first prescription fixed triple therapy with BDP/FF/GB NEXThaler® 88/5/9 in accordance with the marketing authorization
  • COPD Assessment Test (CAT) total score of at least 10 at the day of inclusion
  • to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Asthmatic patients
  • Patients with moderate or severe exacerbations within the 4 weeks prior to enrolment
  • Patients treated with fixed triple therapies within 6 months prior inclusion
  • Patients receiving pulmonary rehabilitation within 3 months prior to inclusion or within 6 months after inclusion
  • Concomitant participation in experimental clinical studies/investigations or participation in experimental clinical studies/investigations within 3 months prior to enrolment into the present study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
500 participants (estimated)
Patient registry
No

Interventions

  • DrugBeclometasone/Formoterol/Glycopyrronium 88 µg/5 µg/9 µg DPI (Trimbow® 88 µg/5 µg/9 µg in NEXThaler device)

    observational, prospective, multicentric, international, cohort study

06

What researchers measure

Primary outcomes

  1. Change of quality of life through CAT (COPD assessement tool) over 6 month period

    To assess change in QoL using the CAT scale over a 6-month follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device • Primary endpoint is the proportion of patients achieving a ≥2-point reduction in CAT total score (MCID) at M6 compared to baseline.

    Time frame: Month 6

Secondary outcomes

  1. Mean change Quality of life through VQ11 questionnaire

    To assess change in QoL using the VQ11 scale over a 6-month follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device • Endpoint is mean VQ11 total score and sub scores described at baseline, M3 and M6

    Time frame: Month 0, Month 3 and Month 6

  2. Proportion of patients achieving a ≥2-point reduction in VQ11 total score

    To assess change in QoL using the VQ11 scale over a 6-month follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device • Endpoint is the proportion of patients achieving a ≥2-point reduction in VQ11 total score (MCID) at M3 and M6 compared to baseline.

    Time frame: Month 0, Month 3 and Month 6

  3. Mean change in Dyspnoea throught "Dyspnea-12 questionnaire"

    To assess changes in dyspnoea using the Dyspnea-12 over a 6-month follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device • Endpoint is D-12 total score and sub scores described at baseline, M3 and M6

    Time frame: Month 0, Month 3 and Month 6

  4. Proportion of patients achieving a 3-point reduction in "Dyspnea-12" total score

    To assess changes in dyspnoea using the Dyspnea-12 over a 6-month follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device • Endpoint is the proportion of patients achieving a 3-point reduction in D-12 total score (MCID) at M3 and M6 compared to baseline.

    Time frame: Month 0, Month 3 and Month 6

  5. Rate of moderate and severe exacerbations at M0, M3 and M6 through eCRF

    To describe the occurrence of moderate to severe exacerbations over a 6- month follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device Endpoint is the proportion of patients with at least a moderate or severe exacerbation (overall and in each category), at baseline (in the previous 12 months), M3 and M6

    Time frame: Month 0, Month 3 and Month 6

  6. Proportion of patients achieving an increase in physical activity throught the a connected device

    To assess changes in physical activity using a connected watch over a 6-month • Endpoint is the proportion of patients achieving an increase in physical activity (≥ 10%-increase in the mean daily number of step) at M3 and M6 compared to baseline. Baseline physical activity (M0) will be defined as the mean of data collected during the first 7 days of connected device wearing watch over a 6-month follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device

    Time frame: Month 0, Month 3 and Month 6

  7. Mean daily number of steps throught the a connected device

    To assess changes in physical activity using a connected watch over a 6-month • Endpoints are the mean daily number of steps and the mean of number of steps during 7 days at M0, M3 and M6 Baseline physical activity (M0) will be defined as the mean of data collected during the first 7 days of connected device wearing watch over a 6-month follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device

    Time frame: Month 0, Month 3 and Month 6

  8. Sleep quality throught the Pittsburgh questionnaire

    • Endpoints are the Pittsburgh questionnaire at M0, M3 and M6 Baseline physical activity (M0) will be defined as the mean of data collected during the first 7 days of connected device wearing.

    Time frame: Month 0, Month 3 and Month 6

  9. Sleep quality throught the a connected device

    To assess changes in sleep quality using a connected device • Endpoints are the mean daily sleep time, the mean of sleep time and the mean daily number of awakenings during 7 days at M0, M3 and M6 Baseline sleep quality (M0) will be defined as the mean of data collected during the first 7 days of connected device wearing.

    Time frame: Month 0, Month 3 and Month 6

  10. Treatment compliance at M3 and M6 through TAI (test inhaler adherence) questionnary

    To assess treatment compliance with BDP/FF/G (88/5/9) in NEXThaler® device • Endpoint is the description of treatment compliance global score at M3 and M6 for COPD using TAI

    Time frame: Month 3 and Month 6

  11. Baseline description of sociodemographic data and medical data through eCRF

    to describe COPD patient, disease and treatment characteristics at initiation of BDP/FF/G (88/5/9) in NEXThaler® device * Endpoints are description of sociodemographic (age, sex, weight, height, education level, occupation), medical data (risk factors exposure including tobacco, disease history) and lung function data (FEV1, FVC, RV, TLC) at baseline * Endpoints are description of comorbidities and associated treatment throughout the study at baseline * Endpoints are description of previous COPD-related treatment at baseline through eCRF

    Time frame: baseline

  12. Treatment tolerance throughout the study through eCRF

    To assess treatment tolerance in COPD patients treated with with BDP/FF/G (88/5/9) in NEXThaler® device To assess patient satisfaction with treatment in COPD patients treated with BDP/FF/GB NEXThaler® 88/5/9

    Time frame: up to 24 weeks

Other outcomes

  1. Correlation between exacerbations occurrence and physical activity

    To assess the association between exacerbations occurrence and physical activity changes Physical activity measured by a connected device over a 6-month follow-up

    Time frame: Month 6

  2. Correlation between exacerbations occurrence and sleep quality

    To assess the association between exacerbations occurrence sleep quality changes Sleep quality changes measured by a connected device over a 6-month follow-up period in COPD patients treated with BDP/FF/G (88/5/9) in NEXThaler® device for COPD

    Time frame: Month 6

  3. Correlation between QoL measured by VQ11 and the CAT through PROM

    To assess the correlation between QoL measured with the VQ11 and the CAT for COPD • Endpoints are value of the Pearson correlation test described at baseline, M3 and M6

    Time frame: Month 0, Month 3 and Month 6

  4. Correlation between QoL measured with the VQ11 and Dyspnea-12 through PROM

    To assess the correlation between QoL measured with the VQ11 and Dyspnea-12 for COPD • Endpoints are value of the Pearson correlation test described at baseline, M3 and M6

    Time frame: Month 0, Month 3 and Month 6

  5. Among patients with the connected device, assess the correlation of sleep quality when measured with connected device and with the Pittsburgh Sleep Quality Index

    Among COPD patients with the connected device, to assess the correlation of sleep quality when measured with connected device and with the Pittsburgh Sleep Quality Index • Endpoints are value of the Pearson correlation test described at baseline, M3 and M6

    Time frame: Month 0, Month 3 and Month 6

  6. Dyspnoea with modified Medical Research Council (mMRC)

    Endpoint is mMRC total score described at baseline, M3 and M6

    Time frame: Month 0, Month 3 and Month 6

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Dec 2024, 16 months after the start.

Of 120 industry-sponsored observational studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's planned 16 months is below that.

Counting every sponsor, half of 589 studies reached it within 26 months; a quarter within 14 and three quarters within 57.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 30, 2023
First posted
Jul 17, 2023
StartActual
Aug 1, 2023
Primary completionEst.
Dec 2024
CompletionEst.
Mar 2025
Last update
Mar 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05948891
Lead sponsor
Chiesi SAS
Collaborators
Kappa Santé
Responsible party
Sponsor
First posted
Jul 17, 2023
Start date
Aug 1, 2023
Primary completion
Dec 2024 (estimated)
Completion
Mar 2025 (estimated)
Last update
Mar 13, 2024

Study contacts

Christine Contré, Dr - Medical Director
Contact
c.contre@chiesi.com
+33147684121
Justine Fiocca, PHARM.D-Medical Advisor
Contact
j.fiocca@chiesi.com
Capucine MORELOT PANZINI, Pr
principal investigator · University Hospital, la pitié salpêtrière
Philippe DEVILLIER, Pr
principal investigator · HOSPITAL, FOCH
Hervé PEGLIASCO, Dr
principal investigator · European Hospital, Marseille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion